Frischer Lab

  • Frischer Lab Research

    The lab studies angiogenesis which is the formation of new vessels from preexisting vasculature which is pathologic in cancer and chronic inflammation.

    • Ewing’s Sarcoma model and neuroblastoma with EGFR Inhibition to Suppress Vascular Proliferation.
    • The Pathogenesis of inflammatory bowel disease IBD which includes both ulcerative colitis and Crohn’s disease.
  • Publications

    Show All

    2013

    Currier, MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic s, Boon L, Goins WF, Frischer JS, Collins MH, Baird WH, Haseley A, Streby KA Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.  VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cellsMol Ther, 2013 May:21(5):1014-23. 

    Knod JL, Donovan EC, Dusing MR, Crawford KM, Chernoguz A. Frischer JS.  VEGFR2 Inhibition in Experimental Murine Colitis Journal of Surgical Research (2013)  184(1):101-107.

    2012

    Chernoguz A, Crawford, K, Vandersall A, Willson T, Denson LA, Frischer JS.Pre-treatment with Anti-VEGF therapy may exacerbate inflammation in experimental acute colitis. J Pediatr Surg. 2012 Feb;47(2):347-54. 

    Chernoguz A, Crawford KM, Donovan EC, Vandersall AE, Berglund C, Cripe TP, Frischer JS. EGFR Inhibition Fails to Suppress Vascular Proliferation and Tumor Growth in a Ewing’s Sarcoma Model. J Surg Res. 2012 Mar;173(1):1-9.


 
  • Contact Us

    Jason Frischer's headshot photo.

    Jason S. Frischer, MD

    Director, Extracorporeal Membrane Oxygenation Program
    Assistant Professor of Surgery and Pediatrics
    University of Cincinnati College of Medicine
    Division of Pediatric General and Thoracic Surgery
    Cincinnati Children’s Hospital Medical Center

    Phone: 513-636-4371
    Fax: 513-636-7657
    Email: jason.frischer@cchmc.org